Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:abacavir
gptkb:lamivudine |
| gptkbp:approvalYear |
2004
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AR02
|
| gptkbp:contains |
300 mg lamivudine
600 mg abacavir |
| gptkbp:contraindication |
severe liver impairment
HLA-B*5701 positive |
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:abacavir/lamivudine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epzicom
|
| gptkbp:indication |
adolescents
adults |
| gptkbp:isCombinationDrug |
true
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:ViiV_Healthcare
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
liver toxicity
lactic acidosis hypersensitivity reaction |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:abacavir
|
| gptkbp:bfsLayer |
6
|